Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scaffidi

Showing results (401-410 of 420) with videos related to

Pageof 42
Sort By:
The Lancet. Haematology|January 21, 2021
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trialTiziano Barbui, Alessandro Maria Vannucchi, Valerio De Stefano, et al.
Seminars in Hematology|December 4, 2018
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study<sup>⁎</sup>Francesca Palandri, Giuseppe A Palumbo, Alessandra Iurlo, et al.
Annals of Hematology|June 1, 2020
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitorsOlga Mulas, Giovanni Caocci, Fabio Stagno, et al.
Oncotarget|November 8, 2017
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosisFrancesca Palandri, Giuseppe Alberto Palumbo, Massimiliano Bonifacio, et al.
NEJM Evidence|February 6, 2024
Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia VeraTiziano Barbui, Alessandro Maria Vannucchi, Valerio De Stefano, et al.
Cancer|March 18, 2023
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcomeFrancesca Palandri, Massimo Breccia, Camilla Mazzoni, et al.
Annals of Hematology|December 7, 2023
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomesTiziano Barbui, Alessandra Carobbio, Valerio De Stefano, et al.
British Journal of Haematology|November 22, 2020
Second primary malignancy in myelofibrosis patients treated with ruxolitinibNicola Polverelli, Elena M Elli, Elisabetta Abruzzese, et al.
The Journal of Allergy and Clinical Immunology. in Practice|December 21, 2020
Scoring the Risk of Having Systemic Mastocytosis in Adult Patients with Mastocytosis in the SkinDavid Fuchs, Alex Kilbertus, Karin Kofler, et al.
Leukemia|May 31, 2019
Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control studyTiziano Barbui, Arianna Ghirardi, Arianna Masciulli, et al.
Pageof 42

Showing results (401-410 of 420) with videos related to

Sort By:
Pageof 42
The Lancet. Haematology|January 21, 2021
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trialTiziano Barbui, Alessandro Maria Vannucchi, Valerio De Stefano, et al.
Seminars in Hematology|December 4, 2018
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study<sup>⁎</sup>Francesca Palandri, Giuseppe A Palumbo, Alessandra Iurlo, et al.
Annals of Hematology|June 1, 2020
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitorsOlga Mulas, Giovanni Caocci, Fabio Stagno, et al.
Oncotarget|November 8, 2017
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosisFrancesca Palandri, Giuseppe Alberto Palumbo, Massimiliano Bonifacio, et al.
NEJM Evidence|February 6, 2024
Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia VeraTiziano Barbui, Alessandro Maria Vannucchi, Valerio De Stefano, et al.
Cancer|March 18, 2023
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcomeFrancesca Palandri, Massimo Breccia, Camilla Mazzoni, et al.
Annals of Hematology|December 7, 2023
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomesTiziano Barbui, Alessandra Carobbio, Valerio De Stefano, et al.
British Journal of Haematology|November 22, 2020
Second primary malignancy in myelofibrosis patients treated with ruxolitinibNicola Polverelli, Elena M Elli, Elisabetta Abruzzese, et al.
The Journal of Allergy and Clinical Immunology. in Practice|December 21, 2020
Scoring the Risk of Having Systemic Mastocytosis in Adult Patients with Mastocytosis in the SkinDavid Fuchs, Alex Kilbertus, Karin Kofler, et al.
Leukemia|May 31, 2019
Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control studyTiziano Barbui, Arianna Ghirardi, Arianna Masciulli, et al.
Pageof 42